Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology

Jak1/2 inhibition suppresses STAT3 phosphorylation that is characteristic of many cancers. Activated STAT3 promotes the transcription of factors that enhance tumor growth, survival, and angiogenesis. AZD1480 is a novel small molecule inhibitor of Jak1/2, which is a key mediator of STAT3 activation....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Loveless, Mary E, Lawson, Deborah, Collins, Michael, Prasad Nadella, Murali V, Reimer, Corinne, Huszar, Dennis, Halliday, Jane, Waterton, John C, Gore, John C, Yankeelov, Thomas E
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Neoplasia Press Inc. 2012
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3281942/
https://ncbi.nlm.nih.gov/pubmed/22355274
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak